The drug candidate was one of three therapies added through the $12.0B Avidity Biosciences acquisition. Following late-stage trial goal misses in the lead neuromuscular program, this model recalculates post-setback net asset value, impairment exposure, and probability-adjusted return across remaining pipeline assets.
M&A & Pipeline Valuation Levers
Simulate trial outcomes, probability adjustments, and discount rates
$12.0B
$0.7B
Original pre-trial valuation: ~$5.5B. Post-miss salvage / biomarker secondary potential.
$6.5B
100%
8.5%
Pipeline Asset
Target / Modality
Phase Status
Model Value
Lead Neuromuscular (Avidity)
AOC Oligonucleotide
Late-Stage Miss
$0.70B
Therapy 2 (Preclinical/P1)
Rare Skeletal Muscle
Active
$3.50B
Therapy 3 (Cardiomyopathy)
Precision RNA
Active
$3.00B
Portfolio Return & Impairment Exposure
Calculated against $12.0B transaction capitalization
Adjusted Portfolio Value
$7.2B
Risk-weighted pipeline
Net Value Delta
-$4.8B
Value vs. acquisition cost
Return on Investment
-40.0%
M&A ROI
Financial Risk Status
High Impairment Risk
Pipeline Asset Value DistributionSuccess Target vs. Post-Miss Reality